Introduction
============

Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality worldwide in patients with type 2 diabetes (T2DM)^[@bib1],\ [@bib2])^. In the management of overall health in diabetic patients, early and accurate identification of the groups at high risk of CAD is important. However, cardiovascular risk assessment based on conventional risk factors such as age, sex, smoking status, blood pressure, and cholesterol showed only moderate performance^[@bib3]--[@bib5])^. Thus, the exploration of new molecules or pathways related to considerable residual risk of CAD is needed. Since CAD is the result of complex metabolic disorders caused by various environmental and genetic factors, an approach to evaluate comprehensive metabolic change could be helpful to increase the mechanistic understanding of atherosclerosis and to identify indicators for high-risk patients.

Metabolomics, the study of small-molecule metabolites that are by-products of a variety of biochemical and cellular processes, is one of the most hopeful omics techniques, and depicts the real-time metabolic status of an organism^[@bib6],\ [@bib7])^. Therefore, metabolomics is a potential tool for identifying biomarkers for better risk classification and for understanding the pathophysiological mechanism of cardiovascular diseases. Non-targeted metabolomic profiling refers to the identification of metabolites using a hypothesis-free approach and, hence, would be useful for discovering novel metabolites.

Capillary electrophoresis-mass spectrometry (CE-MS) is a commonly used tool in metabolome analysis. The major advantage of CE-MS is high separation efficiency and high ability to identify and quantify global polar ionogenic metabolites, such as carbohydrates and amino acids^[@bib8],\ [@bib9])^. Therefore, CE-MS systems have been used in many clinical studies to evaluate metabolic fingerprinting of various biological samples for biomarker discovery and understanding the pathophysiology of diseases^[@bib10]--[@bib13])^.

With this background, we performed a pilot study to identify metabolites associated with future onset of CAD in patients with T2DM using CE-MS analysis.

Methods
=======

Subjects
--------

The current study was based on data retrospectively obtained from the Order-Made multiple Risk Factor Investigation Trial (OMRFIT), which was a prospective multicenter cohort study to investigate the genetic factors for diabetic complications in 4777 Japanese diabetic patients. In the original study, 473 subjects were registered at Osaka University Hospital during January-December 2005 and followed up until 2013 (median follow up period; 8.7 years). In the present study, the subjects were recruited from these 473 subjects and written informed consent was obtained from 176 subjects. Among them, 16 subjects who developed CAD events during the observation period were selected as the CAD-positive group. For this pilot study, a non-CAD control group consisting of 39 subjects was matched to the CAD-positive group for Framingham Coronary Heart Disease Risk Score, diabetes duration, and HbA1c, which are assumed to be clinical factors with a large influence on CAD. The procedure was as follows. After excluding 10 out of 160 non-CAD patients because of missing data, the process of selecting 39 subjects was continued until three factors with a standardized difference of 0.58 or less were found. This cut-off value of standardized difference was calculated based on the formula previously reported ![](jat-26-233-g004.jpg) : number of patients respectively, in the CAD and non-CAD groups)^[@bib14],\ [@bib15])^. The standardized difference in FRS, diabetes duration, and HbA1c between CAD-positive group and selected 39 non-CAD subjects was 0.25, 0.10, and 0.06, respectively.

In the present study, a CAD event was defined as cardiovascular death, acute myocardial infarction, angina pectoris, or coronary revascularization treatment that included coronary intervention and coronary bypass graft. The diagnosis of the occurrence of coronary artery disease was performed by cardiologists based on the clinical symptoms, characteristic ECG changes, cardiac enzyme levels, and findings on coronary angiography and/or echocardiography, according to established guidelines^[@bib16],\ [@bib17])^.

Ethics, Consent, and Permissions
--------------------------------

The Research Ethics Committee of Osaka University Graduate School of Medicine approved the study protocol and the study was conducted in accordance with the principles of the Helsinki Declaration. Written informed consent was obtained from all the subjects after they received a full explanation of the study.

Clinical and Biochemical Analysis
---------------------------------

The clinical and biochemical data at baseline were collected in 2005, the start year of OMRFIT, a longitudinal observation study. Fasting blood samples were collected and HbA1c and serum total and HDL-cholesterol levels were measured using standard laboratory protocols. The following criteria was used to diagnose diabetes: early-morning fasting plasma glucose (PG) ≥ 126 mg/dl, two-hour PG after 75 g glucose load ≥ 200 mg/dl, or causal plasma glucose load ≥ 200 mg/dl. The determination of hypertension (defined as systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 80 mmHg or anti-hypertensive medication use) and dyslipidemia (defined as serum LDL cholesterol ≥ 3.1 mmol/L (120 mg/dl) or serum TG ≥ 1.7 mmol/L (150 mg/dl) or HDL-cholesterol \< 1.0 mmol/L (40 mg/dl) or lipid-lowering medication use) was based on the criteria of the Japan Diabetes Society. The risk of CAD was estimated by FRS, which uses information on age, gender, total and HDL-cholesterol level, blood pressure, smoking status, and the existence of diabetes mellitus^[@bib18])^.

Capillary Electrophoresis Time-of-Flight Mass Spectrometry (CE-TOFMS) Analysis
------------------------------------------------------------------------------

For the metabolome analysis, the frozen stored serum that was collected in 2005, the start year of the longitudinal observation before the development of CAD event, was used. The CE-TOFMS measurement was performed in April 2014 at Human Metabolome Technologies, Inc., Tsuruoka, Japan, using the baseline fasting serum samples that had been stored at −80°C since collection. The CE-TOFMS analysis was operated using the cation-positive mode and anion-negative mode. The serum samples were thawed on ice before preparation. For the extraction of serum metabolites, 50 µl serum samples were added to 450 µl of methanol containing internal standards (Solution ID: H3304-1002, Human Metabolome Technologies, Inc., Tsuruoka, Japan). Then, the samples were mixed with 200 µl Milli-Q water and 500 µl chloroform and were centrifuged at 2300 ×g at 4°C for 5 min. Subsequently, 350 µl of the upper aqueous solution was centrifugally filtered through 5-kDa cut-off filter (Millipore) at 9100 ×g at 4°C for 120 min. The filtrate (400 µl) was centrifugally concentrated and was re-suspended 25 µl Milli-Q water for the CE-TOFMS analysis.

Data Processing
---------------

Peaks were extracted using MasterHands (Keio University, Tsuruoka, Japan) automatic integration software to obtain peak information, including *m/z*, migration time for CE-TOFMS measurement (MT), and peak area. Signal peaks corresponding to isotopomers, adduct ions, and other product ions of known metabolites were excluded, and the remaining peaks were annotated with putative metabolites from the HMT metabolite database based on their MTs and *m/z* values determined by TOFMS. The tolerance range for the peak annotation was configured at ± 0.5 min for MT and ± 10 ppm for *m/z*. In addition, peak areas were normalized against those of the internal standard for cations (MetSul \[methionine sulfone\]) and that for anions (CSA \[D-camphor-10-sulfonic acid\]) and, then, the resultant relative area values were further normalized to the sample amount.

Statistical Analysis
--------------------

The data are reported as mean ± standard deviation (SD) for continuous variables and percentage for dichotomous variables. Unpaired *t*-test was used to compare the means. Pearson\'s chi-squared test was used to compare the categorical variables. Principal component analysis (PCA) and Welch\'s *t*-test were used to analyze the relationships between CAD and the levels of serum metabolites. *p* \< 0.05 was considered statistically significant. The prediction ability of each detected metabolite to discriminate between subjects with and without CAD was examined by receiver-operating-characteristic (ROC) curve analyses. SPSS version 22 (SPSS Inc., Chicago, IL, USA) was used to perform these statistical analyses.

Results
=======

Clinical Characteristics of the Study Population
------------------------------------------------

CAD events occurred in 16 subjects out of 176 (9.1%) during the observation period, and from the 160 subjects without CAD, 39 control subjects who were matched to the CAD group for FRS, diabetes duration, and HbA1c were selected (**[Supplementary Fig. 1](#F2){ref-type="fig"}**). **[Table 1](#T1){ref-type="table"}** lists the baseline clinical characteristics of the study subjects with and without the new onset of CAD during the observation period. Among the subjects who experienced CAD during follow up (males, 88%; age, 66.3 ± 6.1 years; diabetes duration, 17.2 ± 10.1 years; HbA1c, 7.1 ± 0.7%), 10 (63%) subjects had hypertension, 10 (63%) had dyslipidemia, and 8 (53%) had a smoking habit. There were no significant differences in the majority of the clinical variables between the two groups. Half of the subjects (8 of 16) in the CAD group had a history of coronary intervention or coronary artery bypass graft (CABG), whereas no subject of the non-CAD group had history of coronary artery treatment.

![Disposition of study subjects\
In the present study, the subjects were recruited from 473 subjects who were enrolled in the Order-Made multiple Risk Factor Investigation Trial (OMRFIT) at Osaka University Hospital. Among the 176 type 2 diabetic subjects who were enrolled in the present study, 16 subjects who developed CAD events during the observation period were selected as the CAD group. From the 160 subjects without CAD, 39 control subjects who were matched to the CAD group for Framingham Coronary Heart Disease Risk Score, diabetes duration, and HbA1c were selected as the non-CAD group.](jat-26-233-g002){#F2}

###### Baseline clinical characteristics of study subjects with and without new onset of CAD during the observation period

  Characteristics                  Non-CAD group   CAD group      *p* value
  -------------------------------- --------------- -------------- -----------
  Age (years)                      63.7 ± 8.2      66.3 ± 6.1     0.271
  Male gender (n (%))              29 (74)         14 (88)        0.284
  Diabetes duration (years)        16.2 ± 10.0     17.2 ± 10.1    0.990
  BMI (kg/m^2^)                    24.4 ± 3.1      25.1 ± 3.3     0.469
  HbA1c (%)                        7.1 ± 1.0       7.1 ± 0.7      0.841
  Smoking (n (%))                  20 (51)         8 (53)         0.893
  Hypertension (n (%))             33 (85)         10 (63)        0.071
  Systolic BP (mmHg)               138.6 ± 14.2    130.4 ± 21.1   0.101
  Diastolic BP (mmHg)              78.2 ± 12.6     71.8 ± 12.2    0.086
  Dyslipidemia (n (%))             28 (72)         10 (63)        0.498
  HDL cholesterol (mg/dl)          54.9 ± 24.4     47.7 ± 13.6    0.316
  LDL cholesterol (mg/dl)          116.9 ± 31.7    109.1 ± 24.8   0.394
  Framingham risk score (%)        24.3 ± 12.4     27.4 ± 11.2    0.392
  Medication use                                                  
      ACE inhibitor/ARB (n (%))    11 (28)         7 (44)         0.264
      Statin (n (%))               28 (72)         10 (63)        0.498
      Insulin (n (%))              13 (33)         9 (56)         0.115
      Antiplatelet agent (n (%))   23 (59)         11 (69)        0.498

Data are presented as mean ± standard deviation or number with percentage in parentheses. BMI, body mass index; BP, blood pressure; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker

Metabolomic Profiling
---------------------

A total of 104 metabolites were identified from the serum samples after excluding the components of therapeutic medicines and their metabolites, substances suspected as contaminants (e.g., eluted substances from sample storage tubes), and metabolites with unknown identities. Before further analysis, 8 metabolites which were not detected in ≥ 25% of the samples in each group were excluded. Consequently, 96 metabolites were analyzed for association with CAD (**[Supplementary Table 1](#T3){ref-type="table"}**).

###### A list of detected metabolites with known identity by CE-MS analysis in at least 75% of subjects in each group, with and without CAD.

  Metabolite                            Non-CAD group    CAD group         *p* value[1](#tf1){ref-type="table-fn"}
  ------------------------------------- ---------------- ----------------- -----------------------------------------
  Urea                                  27.823 ± 7.339   32.306 ± 17.695   0.341
  Ethanolamine                          0.101 ± 0.034    0.112 ± 0.052     0.419
  Glycine                               0.350 ± 0.129    2.487 ± 0.883     0.101
  Trimethylamine N-oxide                0.225 ± 0.216    0.342 ± 0.307     0.182
  Sarcosine                             0.033 ± 0.014    0.028 ± 0.010     0.219
  *β*-Alanine                           0.038 ± 0.026    0.034 ± 0.011     0.409
  Alanine                               5.630 ± 1.432    6.275 ± 1.693     0.193
  Glycerol                              4.036 ± 1.013    4.266 ± 0.915     0.418
  2-Aminoisobutyric acid                0.439 ± 0.119    0.370 ± 0.093     0.026
  3-Aminoisobutyric acid                0.040 ± 0.044    0.052 ± 0.039     0.334
  GABA                                  0.016 ± 0.010    0.017 ± 0.009     0.545
  Choline                               2.565 ± 2.007    3.261 ± 2.442     0.323
  Serine                                1.635 ± 0.721    1.916 ± 0.932     0.291
  Creatinine                            1.168 ± 0.384    1.943 ± 2.236     0.188
  Proline                               4.667 ± 1.162    4.801 ± 1.786     0.786
  Guanidoacetic acid                    0.049 ± 0.016    0.053 ± 0.020     0.497
  Valine                                6.692 ± 1.479    6.768 ± 1.910     0.889
  Betaine                               1.330 ± 0.288    1.421 ± 0.387     0.411
  Threonine                             1.756 ± 0.562    1.874 ± 0.867     0.623
  Taurine                               0.182 ± 0.067    0.182 ± 0.055     0.990
  Imidazole-4-acetic acid               0.006 ± 0.002    0.006 ± 0.002     0.600
  Thymine                               0.454 ± 0.119    0.364 ± 0.087     0.003
  Pipecolic acid                        0.052 ± 0.057    0.039 ± 0.013     0.165
  Hydroxyproline                        0.151 ± 0.051    0.163 ± 0.089     0.632
  Creatine                              0.957 ± 0.442    0.734 ± 0.240     0.020
  Isoleucine                            3.098 ± 0.869    2.932 ± 1.096     0.594
  Leucine                               6.638 ± 3.916    7.794 ± 5.032     0.419
  Asparagine                            0.169 ± 0.116    0.220 ± 0.155     0.249
  Ornithine                             1.087 ± 0.331    1.132 ± 0.406     0.702
  Aspartic acid                         0.907 ± 0.818    1.252 ± 0.997     0.232
  Hypoxanthine                          0.084 ± 0.031    0.070 ± 0.020     0.047
  Trigonelline                          0.040 ± 0.049    0.043 ± 0.036     0.792
  1H-Imidazole-4-propiolic acid         0.011 ± 0.008    0.026 ± 0.055     0.298
  Stachydrine                           0.314 ± 0.294    0.477 ± 0.529     0.261
  4-Guanidinobutyric acid               0.023 ± 0.010    0.023 ± 0.011     0.839
  *γ*-Butyrobetaine                     0.050 ± 0.012    0.061 ± 0.025     0.126
  Glutamine                             0.411 ± 0.406    0.567 ± 0.495     0.275
  Lysine                                3.263 ± 1.532    3.357 ± 1656      0.847
  Glutamic acid                         6.466 ± 1.503    6.821 ± 2.192     0.560
  Histidine                             0.867 ± 0.442    1.091 ± 0.724     0.265
  N6-Methyllsine                        0.070 ± 0.044    0.062 ± 0.021     0.385
  Carnitine                             1.517 ± 0.255    1.549 ± 0.278     0.693
  Methionine sulfoxide                  0.339 ± 0.166    0.333 ± 0.168     0.903
  Phenylalanine                         2.526 ± 1.351    3.106 ± 1.768     0.251
  1-methylhistidine; 3-methlhistidine   0.167 ± 0.158    0.245 ± 0.286     0.317
  N5-Ethlglutamine                      0.017 ± 0.007    0.022 ± 0.008     0.073
  N-Acetylornithine                     0.015 ± 0.013    0.016 ± 0.013     0.806
  Arginine                              3.169 ± 1.470    3.927 ± 2.470     0.266
  Guanidinosuccinic acid                0.005 ± 0.005    0.016 ± 0.042     0.303
  Citrulline                            0.356 ± 0.127    0.447 ± 0.257     0.194
  Galactosamine; Glucosamine            0.533 ± 0.284    0.350 ± 0.129     0.002
  Paraxanthine                          0.037 ± 0.019    0.033 ± 0.026     0.567
  Tyrosine                              1.149 ± 0.597    1.206 ± 0.728     0.782
  SDMA                                  0.012 ± 0.006    0.018 ± 0.018     0.233
  Tryptophan                            0.822 ± 0.193    0.800 ± 0.238     0.749
  Kynurenine                            0.025 ± 0.007    0.029 ± 0.010     0.127
  Cystine                               0.023 ± 0.012    0.024 ± 0.010     0.882
  Uridine                               0.045 ± 0.012    0.055 ± 0.034     0.259
  Glycerophosphocholine                 0.109 ± 0.026    0.111 ± 0.027     0.821
  Isobutyric acid; Butyric acid         0.043 ± 0.009    0.042 ± 0.009     0.725
  Lactic acid                           8.670 ± 2.617    9.226 ± 2.365     0.449
  Isovaleric acid; valeric acid         0.266 ± 0.079    0.226 ± 0.066     0.063
  3-Hydroxybutyric acid                 0.247 ± 0.192    0.153 ± 0.085     0.015
  2-Hydroxybutyric acid                 0.264 ± 0.087    0.216 ± 0.083     0.065
  Glyceric acid                         0.127 ± 0.043    0.120 ± 0.029     0.505
  Hexanoic acid                         0.048 ± 0.013    0.046 ± 0.012     0.540
  Succinic acid                         0.085 ± 0.017    0.083 ± 0.017     0.650
  2-Hydroxyvaleleric acid               0.063 ± 0.034    0.060 ± 0.028     0.728
  Isethionic acid                       0.006 ± 0.003    0.011 ± 0.012     0.190
  5-Oxoproline                          0.467 ± 0.188    0.545 ± 0.187     0.169
  2-Hydroxy-4-methylvaleric acid        0.010 ± 0.003    0.010 ± 0.002     0.963
  Malic acid                            0.102 ± 0.039    0.096 ± 0.029     0.514
  Threonic acid                         0.098 ± 0.024    0.126 ± 0.093     0.248
  Octanoic acid                         0.020 ± 0.009    0.018 ± 0.007     0.403
  2-Hydroxyglutaric acid                0.042 ± 0.021    0.040 ± 0.014     0.666
  Citramalic acid                       0.032 ± 0.026    0.034 ± 0.015     0.762
  Pelargonic acid                       0.049 ± 0.011    0.040 ± 0.005     0.00009
  Uric acid                             0.050 ± 0.140    0.982 ± 0.280     0.089
  Glycerol 3-phosphate                  0.006 ± 0.002    0.006 ± 0.002     0.922
  Decanoic acid                         0.039 ± 0.013    0.033 ± 0.010     0.075
  cis-Aconitic acid                     0.033 ± 0.014    0.037 ± 0.011     0.251
  Hippuric acid                         0.024 ± 0.028    0.053 ± 0.088     0.210
  Isocitric acid                        0.025 ± 0.009    0.029 ± 0.015     0.452
  Citric acid                           0.613 ± 0.094    0.627 ± 0.177     0.766
  Quinic acid                           0.017 ± 0.016    0.013 ± 0.011     0.322
  Gluconic acid                         0.034 ± 0.011    0.057 ± 0.079     0.266
  Lauric acid                           0.206 ± 0.035    0.214 ± 0.020     0.326
  3-Indoxylsulfuric acid                0.045 ± 0.035    0.020 ± 0.547     0.268
  Myristic acid                         0.010 ± 0.004    0.009 ± 0.005     0.663
  Ascorbate 2-sulfate                   0.013 ± 0.005    0.014 ± 0.004     0.617
  N2-Phenylacetylglutamine              0.019 ± 0.017    0.095 ± 0.268     0.273
  N-acetylneuraminic acid               0.007 ± 0.008    0.004 ± 0.002     0.119
  Prostaglandin E2                      0.065 ± 0.017    0.063 ± 0.020     0.759
  Prostaglandin F2*α*                   0.027 ± 0.010    0.028 ± 0.011     0.780
  Cholic acid                           0.007 ± 0.012    0.005 ± 0.006     0.398
  Glycocholic acid                      0.006 ± 0.005    0.009 ± 0.012     0.198

*p* value from Welch\'s *t*-test comparing the medians.

Metabolites Associate with CAD
------------------------------

Unsupervised PCA was performed to check whether group differentiation was achievable according to the metabolite profiles (**[Supplementary Fig. 2](#F3){ref-type="fig"}**). However, the PCA did not reveal two distinct clusters of individuals, which would be expected if the sampled individuals belonged to two different groups. Then, Welch\'s *t*-test was used to investigate the association of each metabolite with CAD. A significant association with CAD was found in 7 metabolites (pelargonic acid, glucosamine:galactosamine, thymine, 3-hydroxybutyric acid, creatine, 2-aminoisobutyric acid, hypoxanthine) out of 96, and the levels of all of these metabolites were significantly lower in the CAD group compared with the non-CAD group (**[Fig. 1](#F1){ref-type="fig"}**).

![Score plots of unsupervised PCA of all diabetic subjects with and without the onset of CAD.\
To check whether groups could be differentiated according to the metabolite profile, unsupervised PCA was performed. However, it did not reveal two distinct clusters of individuals: CAD subjects (filled circles, *n* = 16) and non-CAD subjects (open circles, *n* = 39).](jat-26-233-g003){#F3}

![Difference in metabolites statistically associated with the onset of CAD. *p* value from Welch\'s *t*-test comparing the medians.](jat-26-233-g001){#F1}

Next, ROC curve analyses were performed to quantify the ability of these 7 metabolites to predict CAD onset (**[Table 2](#T2){ref-type="table"}**). These analyses revealed that perargonic acid and 3-hydroxybutyric acid showed high C-statistic values (0.801, 95% confidential interval (CI); 0.697--0.915, *p* \< 0.001 and 0.716, 95% CI; 0.567--0.866, *p* = 0.012, respectively), indicating that these metabolites were useful in the risk estimation for CAD.

###### The C-statistics (area under the ROC curve) of each metabolite in prediction of CAD.

  metabolite                  AUC     95% confidence interval   
  --------------------------- ------- ------------------------- -------
  Pelargonic acid             0.801   0.697                     0.915
  Glucosamine:galactosamine   0.668   0.512                     0.825
  Thymine                     0.699   0.550                     0.847
  3-Hydroxybutyric acid       0.716   0.567                     0.866
  Creatine                    0.662   0.515                     0.809
  2-Aminoisobutyric acid      0.683   0.528                     0.837
  Hypoxanthine                0.631   0.482                     0.781

ROC, receiver operator characteristics

Discussion
==========

To reduce mortality in the management of diabetes, early prediction of coronary artery disease, and subsequent rapid intervention, are important. Although cardiovascular risk assessment and prediction are performed based on conventional risk factors, validation studies have shown that this approach had only moderate performance^[@bib3]--[@bib5])^. Therefore, detection of unknown pathways related to the progression of atherosclerosis and identification of new prognostic markers for CAD could improve the quality and efficiency of management of overall health in diabetic patients.

In the present pilot study, 104 metabolites were quantified in 55 diabetic subjects with or without CAD by metabolome analysis using CE-TOFMS. Among these metabolites, 7 substrates (pelargonic acid, glucosamine: galactosamine, thymine, 3-hydroxybutyric acid, creatine, 2-aminoisobutyric acid, hypoxanthine) were significantly associated with CAD, and all of these 7 metabolites were lower in the CAD group compared with control subjects. These findings suggest that these 7 metabolites could be novel biomarkers for future onset of CAD. In particular, pelargonic acid and 3-hydroxybutric acid may be promising surrogate markers, because they had discriminatory ability to predict CAD onset in ROC analysis. Furthermore, some of them may play crucial roles in the pathogenesis of CAD.

A few studies have been reported in relevance to the substrates detected in our study and to atherosclerotic disease. Glucosamine is a naturally occurring amino monosaccharide and well known as a precursor for glycosaminoglycans and mucopolysaccharides, major components of joint cartilage, connective tissue, skin, and tendons. There are few data regarding the direct effect of glucosamine on atherosclerotic diseases, and those studies showed controversial results^[@bib19]--[@bib24])^. Some *in vivo* and *in vitro* studies reported protective roles of glucosamine against atherosclerosis with anti-inflammatory effect or inhibition of smooth muscle cell growth^[@bib19]--[@bib21])^, while other studies showed that glucosamine accelerates atherosclerotic change^[@bib22])^ or endoplasmic reticulum stress^[@bib23],\ [@bib24])^. Our data may support the anti-atherosclerotic effect of glucosamine, because its level was significantly lower in patients who developed CAD during the observation period.

Both 3-hydroxybutyric acid and creatine play important roles in energy metabolism. 3-hydroxybutyric acid is a ketone body that is raised in ketosis and can be used as an energy source when usage of glucose is impaired. Recently, the EMPA-REG OUTCOME study showed empagliflozin (a sodium-glucose cotransporter 2 inhibitor) improved cardiovascular mortality and hospitalization for heart failure^[@bib25])^. It is considered that one of the possible reasons for this beneficial effect of empagliflozin is due to a function of 3-hydroxybutyric acid as alternative fuel for the energy metabolism of cells^[@bib26],\ [@bib27])^. Furthermore, 3-hydroxybutyric acid may suppress vascular inflammation leading to atherosclerosis. The increased expression of NOD-like receptor family, pyrin domain-containing 3 inflammasome components (NLRP3) and apoptosis-associated speck-like protein (ASC), in monocytes has been found to be one of the mechanisms that links T2DM and vascular inflammation^[@bib28]--[@bib30])^. Interestingly, a recent study has shown that 3-hydroxybutyric acid reduces NLRP3 inflammasome-mediated interleukin (IL)-1*β* and IL-18 production in human monocytes^[@bib31])^. Creatine also functions as a component in the cellular energy shuttle system. A previous meta-analysis has shown that phosphocreatine administration in patients with acute or chronic heart disease may reduce all-cause short-term mortality and improve left ventricular ejection fraction^[@bib32])^. Other studies also reported that creatine can reduce myocardial stunning^[@bib33])^ or infarct size of brain^[@bib34])^ in ischemic mouse model. However, the direct effect of both of these two metabolites on atherosclerosis has not been evaluated, and it is not clear whether these can reduce the onset of CAD.

Thymine is a pyrimidine nucleobase, and 2-aminoisobutyric acid is an end-product of pyrimidine metabolism. Hypoxanthine is a purine derivative and a reaction intermediate in the metabolism of adenosine and in the formation of nuclei acids by the salvage pathway. Among these substrates related to nucleic acid and its metabolism, hypoxanthine has been reported to be associated with atherosclerosis. It has been reported that hypoxanthine increased serum cholesterol levels and the atherosclerotic plaque area with increasing reactive oxygen species (ROS) production in ApoE-knockout mice^[@bib35])^. Furthermore, it has been also reported that hypoxanthine aggravated myocardial and renal graft ischemia/reperfusion injury by ROS^[@bib36],\ [@bib37])^. Although these results seem to be inconsistent with our data, the direct impact of hypoxanthine on atherosclerosis and detailed mechanism are still unclear.

Pelargonic acid is a nine-carbon, chained, monocarboxylic acid that occurs in epidermis and blood in humans, and is known as a substance associated with body odor. Although the levels of this metabolite were associated with the future onset of CAD in our study, little is known regarding the association of these metabolites with atherosclerotic disease.

Interestingly, Suhre K *et al.* reported that a multiplatform metabolomics study showed increased serum 3-hydroxybutyric acid level, decreased pelargonic acid level, and unchanged creatine and hypoxanthine levels in type 2 diabetic patients compared with healthy subjects^[@bib38])^. Our findings and theirs suggest the possibility that pelargonic acid is related to the onset of CAD under diabetic conditions. On the other hand, 3-hydroxybutyric acid, creatine and hypoxanthine may be associated with CAD independent of the presence of type 2 diabetes. These hypotheses need to be verified by a further clinical intervention study with large sample size. Regarding 2-aminoisobutyric acid, glucosamine and thymine, no reports have compared serum levels between patients with DM and non-diabetic subjects and, thus, further investigations would be necessary to clarify the associations between these metabolites and type 2 diabetes.

Our study has further several limitations. First, the number of the study subjects was too small to lead a robust conclusion. Furthermore, we performed multiple statistical analyses in these subjects, which would generate false-positive results derived from multiple testing. If strict Bonferroni\'s multiple comparison procedure was applied for statistical tests to control the family-wise type 1 error to \< 0.05, the corrected level of significance was supposed to be 5.2\*10^−4^ \[= 0.05/96\]. This correction revealed that only pelargonic acid remained to be significantly associated with CAD. Second, although FRS, HbA1c, and diabetes duration was matched between subjects having experienced CAD and control subjects, the small sample size in our pilot study does not allow adjustment for other clinical variables. Therefore, we could not exclude the possibility that our results were influenced by the clinical background. Similarly, since the number of subjects with CAD was small, the CAD group included subjects who had CAD history at baseline and we could not analyze the data in this regard. Further studies with large sample size would be necessary to confirm our findings. Third, the serum samples used for metabolome analysis had been in storage for about 10 years before the analysis. The long-term stability of the metabolites in serum stored at −80°C has not been evaluated. Moreover, some metabolites could change in the process of serum generation, because platelets release proteins and metabolites into the serum during clotting at room temperature according to previous reports^[@bib39]--[@bib41])^. On the other hand, another study showed that serum samples are more suitable for biomarker detection, because of good reproducibility of serum metabolite measurements and generally higher concentrations of the metabolites in serum than in plasma^[@bib42])^. Anyway, it was reported that there were some differences in metabolite concentrations between serum and plasma, while these profiles were highly correlated. Our pilot study using samples taken from normal subjects also revealed similar results: there were differences in absolute concentration between the two matrices, while overall correlation was high (data not shown). Thus, to increase our confidence, our findings should be supported by further testing under different sample conditions such as short-term storage or plasma. Fourth, we could not draw any conclusion from the present study as to whether there are direct relationships between the detected metabolites and atherosclerosis. Future studies using *in vivo* or *in vitro* models will be necessary to elucidate this point. Finally, although CE-MS analysis is able to evaluate global ionogenic compounds simultaneously, single analysis cannot fully cover the comprehensive metabolic profile of a biological sample. A combination with other MS analysis would enable investigation of metabolomic signatures with broader coverage. Notwithstanding these limitations, our study indicates that difference of specific metabolites could be associated with future onset of CAD in patients with T2DM.

In conclusion, we identified 7 metabolites related to long-term future onset of CAD in Japanese patients with T2DM using current technology, CE-TOFMS.
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